FDA’s Latest PR Push: Protecting the Reputation of Generic Drugs
This article was originally published in RPM Report
Executive Summary
The public’s acceptance of generic drugs is at an all-time high. But manufacturing issues, shortages of life-saving medications and questions about the overall quality of generics are testing the system like never before. FDA’s tough love message to industry: fix the manufacturing problems—or risk your reputation.
You may also be interested in...
Growing Pains for Generic Drugs: OGD Gains Respect, But Loses Geba
FDA’s Office of Generic Drugs was at the start of a turnaround: $299 million in new user fees to clear a big ANDA backlog and fund overseas inspections, an elevated status within the Center for Drugs and a brand-new director to steer the ship. But there have been some bumps in GDUFA implementation, and OGD’s new director, Gregory Geba, has abruptly left the agency. What next for FDA’s generic drug oversight?
FDA Generics Research Forges Ahead After Agency’s Bupropion Mea Culpa
In an unusual essay in the New England Journal of Medicine, CDER Director Janet Woodcock acknowledges that “the conservative approach did not provide the right conclusion regarding therapeutic equivalence in a timely manner.”
Generic Bupropion XL Must Be Retested; Teva/Impax 300 mg Withdrawn After Efficacy Concerns
In what appears to the first downgrade of a generic equivalency based on patient complaints, FDA changes the high dose of the Teva/Impax product from AB to BX. The four other generic manufacturers of 300 mg bupropion extended-release must conduct their own bioequivalence tests, but FDA does not expect problems because they are differently formulated than the Teva/Impax version.